David Lockhart, ReCode Therapeutics CEO

Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

David Lock­hart did not see the me­te­oric rise of mes­sen­ger RNA and lipid nanopar­ti­cles com­ing.

Thanks to the world­wide fight against Covid-19, mR­NA — the ge­net­ic code that can be en­gi­neered to turn the body in­to a mi­ni pro­tein fac­to­ry — and LNPs, those tiny bub­bles of fat car­ry­ing those in­struc­tions, have found their way in­to hun­dreds of mil­lions of peo­ple. With­in the biotech world, pi­o­neers like Al­ny­lam and In­tel­lia have demon­strat­ed just how ver­sa­tile LNPs can be as a de­liv­ery ve­hi­cle for any­thing from siR­NA to CRISPR/Cas9.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters